Please login to the form below

Not currently logged in
Email:
Password:

UCB’s Mark Bodmer elected to BIA board

Will hold the position for a three-year fixed term

ucb mark bodmerUCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).

Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.

As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.

Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.

His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.

10th November 2014

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics